Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
438 studies found for:    "hemophilia"
Hide Display Options

Display Options

Study Details
Participant Details
Rank Status Study
1 Completed Bleeding Symptoms of Carriers of Hemophilia A and B
Condition: Hemophilia
2 Completed A Feasibility Study to Collect Data in Patients With Haemophilia
Condition: Hemophilia
Intervention: Other: Laboratory variables
3 Active, not recruiting Inhibitor Development in Patients With Hemophilia A Undergoing Surgery
Condition: Hemophilia A
4 Completed Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A
Condition: Hemophilia A
Interventions: Biological: Biostate® [SP];   Biological: Biostate® [RP]
5 Completed Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A
Condition: Hemophilia A
Intervention: Drug: ReFacto AF
6 Completed Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery
Condition: Hemophilia A
Intervention: Drug: ReFacto
7 Completed Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
Condition: Hemophilia A
Interventions: Drug: ReFacto;   Drug: Advante
8 Unknown  Turkish Acquired Haemophilia Registry
Condition: Acquired Haemophilia
Intervention: Drug: rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin
9 Completed Study Evaluating rFIX; BeneFIX in Severe Hemophilia B
Condition: Hemophilia B
Intervention: Drug: BeneFIX
10 Completed Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use
Condition: Hemophilia B
11 Unknown  Musculoskeletal Function in Hemophilia
Condition: Hemophilia
12 Completed Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients
Condition: Hemophilia A
Interventions: Biological: Moroctocog alfa ( AF-CC);   Procedure: Laboratory tests
13 Unknown  Quality of Life in Adult Patients With Severe Haemophilia in Turkey
Condition: Haemophilia
14 Recruiting Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A
Condition: Haemophilia A
Intervention: Biological: Optivate 500IU
15 Completed Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A
Condition: Hemophilia A
Interventions: Genetic: ReFacto AF;   Genetic: B-Domain deleted Recombinant Factor VIII;   Genetic: BDDrFVIII
16 Completed
Has Results
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment
Condition: Hemophilia A
Intervention: Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
17 Completed Phase I/IIa Study of FIXFc in Hemophilia B Patients
Condition: Hemophilia B
Intervention: Drug: rFIXFc
18 Active, not recruiting A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: BAY94-9027
19 Completed Canadian Hemophilia Prophylaxis Study
Condition: Severe Hemophilia A
Intervention: Biological: Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)
20 Recruiting Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."
Condition: Hemophilia A
Intervention: Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.